Increasing high-density lipoprotein cholesterol: an update on fenofibrate

Area of Science:

• Cardiovascular Medicine
• Endocrinology
• Pharmacology

Background:

• Low high-density lipoprotein cholesterol (HDL-C) is linked to coronary artery disease and metabolic syndrome features, common in type 2 diabetes and abdominal obesity.
• Fenofibrate is a medication known to influence lipid profiles.

Purpose of the Study:

• To evaluate the efficacy of fenofibrate in increasing HDL-C levels across various dyslipidemic states.
• To compare fenofibrate's HDL-C raising effects with statins.
• To explore fenofibrate's pleiotropic effects on metabolic syndrome and its impact on coronary artery disease progression.

Main Methods:

• Analysis of results from three independent clinical trials investigating fenofibrate's effects on HDL-C.
• Comparison of fenofibrate's efficacy with statins based on published trial data.
• Review of angiographic evidence from the Diabetes Atherosclerosis Intervention Study (DAIS).

Main Results:

• Fenofibrate consistently increases HDL-C levels, with a more pronounced effect at lower baseline levels.
• Fenofibrate demonstrates a greater absolute increase in HDL-C compared to statins, making the 40-mg/dL target more achievable.
• Fenofibrate exhibits beneficial pleiotropic effects on metabolic syndrome components and may slow coronary artery disease progression in type 2 diabetes patients.

Conclusions:

• Fenofibrate is effective in raising HDL-C across diverse dyslipidemic conditions and surpasses statins in absolute HDL-C increase.
• Beyond lipid modification, fenofibrate's pleiotropic actions contribute to clinical benefits, particularly in patients with metabolic syndrome.
• Fenofibrate shows promise in managing coronary artery disease progression in type 2 diabetes, with ongoing trials like FIELD expected to provide further insights.